Compare HYPR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | CGTX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.4M | 79.6M |
| IPO Year | 2021 | 2021 |
| Metric | HYPR | CGTX |
|---|---|---|
| Price | $0.67 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.03 | ★ $3.33 |
| AVG Volume (30 Days) | ★ 893.1K | 460.9K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $49.18 | N/A |
| Revenue Next Year | $29.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.70 | $0.55 |
| 52 Week High | $1.94 | $1.83 |
| Indicator | HYPR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 35.29 |
| Support Level | $0.70 | $0.55 |
| Resistance Level | $1.05 | $1.18 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 16.71 | 37.44 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).